<DOC>
	<DOCNO>NCT00377598</DOCNO>
	<brief_summary>The purpose study evaluate efficacy TAK-583 , daily ( QD ) , relieve pain subject postherpetic neuralgia .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability Study TAK-583 Subjects With Postherpetic Neuralgia</brief_title>
	<detailed_description>Postherpetic neuralgia define neuropathic pain still present 3 month follow heal herpes zoster rash . Symptoms postherpetic neuralgia may include complex combination symptom , include deep aching , shoot burn pain , sensory deficit , hyperalgesia , allodynia , paresthesia , dysesthesia . Postherpetic neuralgia common elderly , debilitate effect patient . The commonly prescribed treatment tricyclic antidepressant anticonvulsant , however treatment effective approximately half subject may also undesirable side effect ( eg , dizziness somnolence ) . TAK-583 synthetic compound development Takeda Global Research &amp; Development Center , Inc. treatment neuropathic pain delay progression diabetic neuropathy . Individuals want participate study require provide write informed consent . Study participation anticipate 11 Weeks . Multiple procedures occur visit may include fasting , blood collection , urine collection , vital sign , body height weight , physical examination electrocardiograms .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<criteria>Male female subject postherpetic neuralgia whose pain present &gt; 3 month follow heal herpes zoster rash . Subjects mean pain intensity score 4 ( determine least 4 daily recording pain intensity 11point numerical scale precede 7 day ) baseline phase . Subjects age 50 year . The female subject childbearing potential ( eg , sterilize , postmenopausal ) . Malignancy within past 2 year exception basal cell carcinoma . Subjects undergone neurolytic neurosurgical therapy postherpetic neuralgia . Clinically significant , actively treat unstable hepatic , biliary , respiratory , renal , rheumatologic , hematologic illness , unstable cardiovascular disease assess investigator . WBC less 2500 , ANC le 1500 , platelets less 100,000 ; ALT , AST alkaline phosphatase great 1.5x ULN ; total bilirubin great equal 1.2 time upper limit normal ( exclude Gilbert 's Disease ) ; predict GFR use Cockcroft Gault formula less equal 40 mL/min . Subjects great 5 red blood cell per highpower field urinalysis . Subjects albumin/creatinine ratio untimed ( `` spot '' ) morning urine specimen great upper limit normal . Subjects immunocompromised clinically significant haematological abnormality . Subjects history HIV infection . Subjects positive hepatitis panel ( include hepatitis B surface antigen , antibody hepatitis B core antigen , antibody hepatitis B surface antigen , antibody hepatitis C virus ) , except subject positive antibody hepatitis B surface antigen receive hepatitis B vaccination history serological evidence liver disease . Subjects severe pain may impair self assessment pain due postherpetic neuralgia . Subjects participate clinical trial investigational drug and/or agent within 30 day prior baseline . Subjects receive TAK583 previous clinical study . Subjects donate 400 mL blood 90 day prior begin study . Subjects history alcohol illicit drug abuse past 2 year Clinically significant abnormal 12 lead electrocardiogram , include QT interval correct heart rate great 450 m confirm repeat electrocardiogram .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Herpes Zoster</keyword>
	<keyword>Neuralgia</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>